DQIS — Register of Scientific Objections v20

Supplementary document to the DQIS Consolidated Framework v22.0 (Zenodo DOI: 10.5281/zenodo.19855263). Register of scientific objections identified during preparation for academic validation of the DQIS framework — Distributed Quorum-Inspired Immune Surveillance. 22 objections addressed across five categories: mathematical, biological, engineering, clinical, and empirical. Version 20.0 (May 2026) — principal updates: O18 RESOLVED with direct empirical measurements (GBM θ=0.199 on 7,911 real cells; PDAC θ=1.214 on 11,448 real cells). O20 RESOLVED — datasets downloaded and analysed. O21 added: normal pancreas intrinsically cold (θ=1.107) — biological explanation (PDX1/HNF1B/PTF1A). O22 added: IPS module resolves PDAC — 15.5× penetrance signal, P(false alarm)=0.0003. O10 corrected: sensitivity table now uses correct k=3 Monte Carlo values (prior v11.0 k=5 values were erroneous). Status by objection: O1 — p_i empirical grounding: T-γ* and T-δ on target with existing technology; T-β p_i=0.004 median (AND-gate M/E, Monte Carlo 10,000 iterations); T-α v3.0 p_i=0.0003–0.002 (triple-AND-gate, best channel in system). O2 — Channel independence: empirically validated GSE72056; inter-M/E LTD≈0; θ=0.17 canonical; balanced quorum eliminates mTOR hub by construction. O3 — Population-level selective pressure: O3-A structurally mitigated by Pattern Drift Sensor; O3-B (global coordination) open as infrastructure requirement. O4 — T-ε reachability p_i=0.01: histotype-dependent; already on target for HER2+/EGFR-amplified. O5 — DQIS-J paediatric procedures: resolved v14.0 — 2 lifetime procedures; self-sustaining threshold effect. O6 — T-γ* temporal criterion: resolved — NFAT-like integrator, 3–4 brief contacts to threshold. O7 — CHIP clonal drift: managed — pre-infusion conditioning + cfDNA barcoding every 12–18 months + selective iC9 reset. O8 — Epigenetic transgene silencing: OPEN — SFFV+AAVS1-intron1+150bp computationally optimal; T-cell organoid validation required before Phase I. O9 — P_quorum in TME: RESOLVED v12.0 — transit model; P_quorum ≥99.93% all tumor phases; detection threshold N~3×10³ cells. O10 — Bulk vs single-cell correlations: corrected v13.0 — ρ_sc ≤ ρ_bulk for inter-group pairs; θ=0.17 is upper bound; k=3 Monte Carlo is correct reference. O11 — Ci-VSP immunogenicity: resolved Phase 0 — H→Q mutation recommended before Phase I; partially open for Phase I. O12 — CDIC dormant cells: managed — T-δ and T-ε cover structurally; pregnancy contraindication for CDIC mode (Medium/High profiles only). O13 — HLA silencing and NK missing self: resolved — HLA-E in construct; pool 6.7× above threshold. O14 — Penn Medicine data transferability to children: partially resolved — N_ss 5–9× above threshold computationally; preclinical mouse model required before Phase I. O15 — Brain reporter gap: RESOLVED v14.0 — S_tm + hepatic S₂ cascade; blue urine 11–24h from brain. O16 — T-α self-activation: RESOLVED MATHEMATICALLY — triple-AND-gate v3.0; p_i=0.0003–0.002 from literature. O17 — Tonic signaling exhaustion: RESOLVED MATHEMATICALLY — PAA ε(10y)=0.921; doxycycline+tet-on analytically proven. O18 — θ cold tumors: RESOLVED WITH DATA — GBM θ=0.199 (NOT cold); PDAC θ=1.214 (confirmed cold); IPS resolves PDAC. O19 — Magenta Therapeutics closure: RESOLVED — replaced with Jasper Therapeutics (briquilimab, Phase 1b Nature Medicine 2025). O20 — Data access bottleneck: RESOLVED — datasets downloaded and analysed May 2026. O21 — Normal pancreas intrinsically cold: RESOLVED — biological explanation; IPS discriminates where θ cannot. O22 — IPS module PDAC detection: RESOLVED — 15.5× penetrance signal; IPMN early warning 10.1×; P(false alarm)=0.0003; no construct modification required. No open structural flaws. O8 (epigenetic silencing) and O14 (paediatric data transferability) require standard preclinical validation, not conceptual breakthroughs. Not a peer-reviewed publication. Prior art deposit — CC BY 4.0. Contact: [email protected] documents: - DQIS Consolidated Framework (main document): https://zenodo.org/records/19877553 - Addendum I — Temporal Stratification of Tail Dependence Risk: https://zenodo.org/records/19877810

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-05-02
DOI
https://doi.org/10.5281/zenodo.19983153
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DQIS — Register of Scientific Objections v20

DQIS Research Group
Zenodo (CERN European Organization for Nuclear Research)
Monoclonal and Polyclonal Antibodies Research
article

DQIS — Register of Scientific Objections v20

DQIS Research Group
article en

Abstract

Supplementary document to the DQIS Consolidated Framework v22.0 (Zenodo DOI: 10.5281/zenodo.19855263). Register of scientific objections identified during preparation for academic validation of the DQIS framework — Distributed Quorum-Inspired Immune Surveillance. 22 objections addressed across five categories: mathematical, biological, engineering, clinical, and empirical. Version 20.0 (May 2026) — principal updates: O18 RESOLVED with direct empirical measurements (GBM θ=0.199 on 7,911 real cells; PDAC θ=1.214 on 11,448 real cells). O20 RESOLVED — datasets downloaded and analysed. O21 added: normal pancreas intrinsically cold (θ=1.107) — biological explanation (PDX1/HNF1B/PTF1A). O22 added: IPS module resolves PDAC — 15.5× penetrance signal, P(false alarm)=0.0003. O10 corrected: sensitivity table now uses correct k=3 Monte Carlo values (prior v11.0 k=5 values were erroneous). Status by objection: O1 — p_i empirical grounding: T-γ* and T-δ on target with existing technology; T-β p_i=0.004 median (AND-gate M/E, Monte Carlo 10,000 iterations); T-α v3.0 p_i=0.0003–0.002 (triple-AND-gate, best channel in system). O2 — Channel independence: empirically validated GSE72056; inter-M/E LTD≈0; θ=0.17 canonical; balanced quorum eliminates mTOR hub by construction. O3 — Population-level selective pressure: O3-A structurally mitigated by Pattern Drift Sensor; O3-B (global coordination) open as infrastructure requirement. O4 — T-ε reachability p_i=0.01: histotype-dependent; already on target for HER2+/EGFR-amplified. O5 — DQIS-J paediatric procedures: resolved v14.0 — 2 lifetime procedures; self-sustaining threshold effect. O6 — T-γ* temporal criterion: resolved — NFAT-like integrator, 3–4 brief contacts to threshold. O7 — CHIP clonal drift: managed — pre-infusion conditioning + cfDNA barcoding every 12–18 months + selective iC9 reset. O8 — Epigenetic transgene silencing: OPEN — SFFV+AAVS1-intron1+150bp computationally optimal; T-cell organoid validation required before Phase I. O9 — P_quorum in TME: RESOLVED v12.0 — transit model; P_quorum ≥99.93% all tumor phases; detection threshold N~3×10³ cells. O10 — Bulk vs single-cell correlations: corrected v13.0 — ρ_sc ≤ ρ_bulk for inter-group pairs; θ=0.17 is upper bound; k=3 Monte Carlo is correct reference. O11 — Ci-VSP immunogenicity: resolved Phase 0 — H→Q mutation recommended before Phase I; partially open for Phase I. O12 — CDIC dormant cells: managed — T-δ and T-ε cover structurally; pregnancy contraindication for CDIC mode (Medium/High profiles only). O13 — HLA silencing and NK missing self: resolved — HLA-E in construct; pool 6.7× above threshold. O14 — Penn Medicine data transferability to children: partially resolved — N_ss 5–9× above threshold computationally; preclinical mouse model required before Phase I. O15 — Brain reporter gap: RESOLVED v14.0 — S_tm + hepatic S₂ cascade; blue urine 11–24h from brain. O16 — T-α self-activation: RESOLVED MATHEMATICALLY — triple-AND-gate v3.0; p_i=0.0003–0.002 from literature. O17 — Tonic signaling exhaustion: RESOLVED MATHEMATICALLY — PAA ε(10y)=0.921; doxycycline+tet-on analytically proven. O18 — θ cold tumors: RESOLVED WITH DATA — GBM θ=0.199 (NOT cold); PDAC θ=1.214 (confirmed cold); IPS resolves PDAC. O19 — Magenta Therapeutics closure: RESOLVED — replaced with Jasper Therapeutics (briquilimab, Phase 1b Nature Medicine 2025). O20 — Data access bottleneck: RESOLVED — datasets downloaded and analysed May 2026. O21 — Normal pancreas intrinsically cold: RESOLVED — biological explanation; IPS discriminates where θ cannot. O22 — IPS module PDAC detection: RESOLVED — 15.5× penetrance signal; IPMN early warning 10.1×; P(false alarm)=0.0003; no construct modification required. No open structural flaws. O8 (epigenetic silencing) and O14 (paediatric data transferability) require standard preclinical validation, not conceptual breakthroughs. Not a peer-reviewed publication. Prior art deposit — CC BY 4.0. Contact: [email protected] documents: - DQIS Consolidated Framework (main document): https://zenodo.org/records/19877553 - Addendum I — Temporal Stratification of Tail Dependence Risk: https://zenodo.org/records/19877810

Zenodo (CERN European Organization for Nuclear Research)
Industry, innovation and infrastructure
Openalex Percentile: Top 8%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.